Imagine shining a flashlight into a material and watching the light bend backward—or in an entirely unexpected direction—as ...
Exelixis (EXEL) stock analysis: 14x 2026E EPS vs. sector, cabozantinib growth, zanzalintinib upside, and FDA/Q4 catalysts.
Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...
If you really want to make a positive change in the political climate, you could run for office. But that’s not a very practical option for most people. To be able to spread light and love, you need ...
Immutep ( (IMMP)) has issued an announcement. On 22 December 2025, Immutep reported positive initial results from a placebo-controlled, double-blind first-in-human Phase I trial of IMP761, its ...
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology ...
Anixa Biosciences ( (ANIX)) just unveiled an announcement. On December 11, 2025, Anixa Biosciences announced positive final data from its Phase 1 clinical trial of an investigational breast cancer ...
The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...
Four years after the Taliban’s return to power in Kabul, Afghanistan faces a paradox. To the outside world, the regime’s restrictions — particularly on women and civil liberties — make positive change ...
SAN FRANCISCO and BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for ...
53% response rate in PD-L1 negative patients, comparing favorably to historical response of 23-32% with standard of care chemoimmunotherapy 60% response rate in 10 patients with STK11, KEAP1, and/or ...
Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer 53% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results